FindTrial
Sign In

Prospective randomized controlled study of anti-platelet therapy in atrial fibrillation patients undergoing percutaneous coronary intervention

Individualized anti-platelet therapy in atrial fibrillation patients undergoing percutaneous coronary intervention

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17013854
Enrollment
Unknown
Registered
2017-12-11
Start date
2017-12-01
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease, atrial fibrillation

Interventions

VASP-guided group:VASP guiding
Control group:clopidogrel fixed dose

Sponsors

Shanghai East Hospital, Tongji University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria are as follows: 1) age between 18 and 80 years, 2) preexisting diagnosis of paroxysmal, persistent or permanent AF, 3) one of 2 indications: refractory angina pectoris in addition to optimal medical therapy; silent ischemia on radionuclide imaging.

Exclusion criteria

Exclusion criteria: Exclusion criteria includes: cardiac arrest, New York Heart Association (NYHA) III/IV function, platelet count < 100×109/L, creatinine clearance rate (Ccr) < 25 mL/min.

Design outcomes

Primary

MeasureTime frame
VASP;—

Countries

China

Contacts

Public ContactXiaodong Wang

Shanghai East Hospital, Tongji University School of Medicine

1978wangxiaodong@163.com+86 18321932678

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 24, 2026